Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate Cancer

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

278

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

September 30, 2009

Study Completion Date

December 31, 2009

Conditions
Prostate Cancer
Interventions
DRUG

Degarelix

"Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).~Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study."

DRUG

Degarelix

"Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).~Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study."

DRUG

Degarelix

"Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).~Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study."

Trial Locations (23)

Unknown

UZ Gasthuisberg Leuven, Leuven

Helsinki University Hospital, Maria Hospital, Building 11, Helsinki

Central Hospital, North Karelian, Joensuu

Oulu University Hospital, Oulu

Tampere University Hospital, Tampere

Fédération d'Urologie et Néphrologie, BP69 Hôpital Pasteur, Nice

Gemeinschaftspraxis Dres Effert und Benedic, Aachen

Clinical Center Novi Sad, Clinic of Urology, Novi Sad

Academic Medical Center, Urology, Amsterdam

St. Elisabeth Hospital, Tilburg

"Centrul Medical Privat Prof. Dr. Ioiart Ioan", Arad

"Clinical Hospital Prof. Dr. Theodor Burghele, Urology Department", Bucharest

University CF Hospital No. 2, Bucharest

Andros Clinic, Saint Petersburg

City Hospital #15, Saint Petersburg

City Hospital #26, Saint Petersburg

Pavlov State Medical University, Outpatient Diagnostic Center affiliated with the Urology Department, Saint Petersburg

Pavlov State Medical University, Urology Department, Saint Petersburg

Clinical Center of Serbia, Institute of Urology and Nephrology, Belgrade

Mount Vernon Cancer Centre, Marie Cuire Research Wing, Northwood

Castle Hill Hospital, Hull

Ward 13, NHS Forth Valley Acute Operating Division, Falkirk and District Royal Infirmary, Majors Loans, Falkirk

Level 7, Urology Research Unit, Derriford Hospital, Plymouth

Sponsors
All Listed Sponsors
lead

Ferring Pharmaceuticals

INDUSTRY